Pfizer (PFE) Enterprise Value (2009 - 2026)

Pfizer has disclosed Enterprise Value across 18 years of filings, most recently posting -$12.8 billion for Q1 2026.

• In Q1 2026, Enterprise Value rose 24.95% year-over-year to -$12.8 billion; the TTM figure through Mar 2026 stood at -$12.8 billion (up 24.95% YoY), while the FY2025 annual figure was -$13.3 billion, up 34.12% from the prior year.
• Enterprise Value improved to -$12.8 billion in Q1 2026, from -$13.3 billion in the prior quarter.
• Over the last five years, Enterprise Value for PFE reached as high as -$6.8 billion in Q2 2024 and fell as low as -$44.5 billion in Q3 2023.
• The 5-year median for Enterprise Value is -$17.0 billion (2025), against an average of -$20.9 billion.
• Annual changes were most pronounced in 2024 — Enterprise Value surged 84.67% — and 2025, when it plunged 89.48%.
• A 5-year view of Enterprise Value shows it stood at -$22.5 billion in 2022, then jumped by 44.76% to -$12.4 billion in 2023, then plunged by 62.56% to -$20.2 billion in 2024, then soared by 34.12% to -$13.3 billion in 2025, then grew by 3.95% to -$12.8 billion in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$12.8 billion, -$13.3 billion, and -$14.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.